Literature DB >> 19327642

Methadone antinociception is dependent on peripheral opioid receptors.

Li He1, Joseph Kim, Chrissi Ou, Whitney McFadden, Richard M van Rijn, Jennifer L Whistler.   

Abstract

UNLABELLED: Morphine and methadone are both high-affinity, potent mu-opioid peptide (MOP) receptor analgesics. In this report, we compared the antinociceptive potencies of these 2 drugs when administered subcutaneously (s.c.), intrathecally (i.t.), or intracerebroventricularly (i.c.v.) in both rat and mouse, using the tail-flick assay. We found that both morphine and methadone were potently antinociceptive when the drugs were administered s.c., showing comparable AD50 values in both species. However, the antinociception produced by methadone, when it was administered centrally, was much weaker than that produced by centrally administered morphine. Specifically, the AD50 value for methadone antinociception was more than 30-fold higher at both the i.t. and i.c.v. sites in mouse and not measurable in rat. Naloxone methiodide (NLX-M), a peripherally restricted antagonist, was used to further examine the relative contribution of central versus peripheral sites to morphine and methadone antinociception. NLX-M, when administered s.c., blocked the antinociceptive effect of either systemically or centrally administered methadone but had little effect on the antinociception produced by centrally administered morphine. Furthermore, centrally administered NLX-M significantly blocked antinociception produced by centrally administered morphine but not that produced by centrally administered methadone. Together, these results suggest that methadone antinociception is significantly dependent on an action of the drug at peripheral sites and could provide novel insight into the neural mechanisms that distinguish morphine versus methadone antinociception. PERSPECTIVE: Methadone is often used as an alternative for pain management. The present study shows that a peripheral action plays a crucial role in methadone antinociception. This finding could have significant clinical relevance for the use of methadone versus morphine for the treatment of certain types of pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327642      PMCID: PMC2952445          DOI: 10.1016/j.jpain.2008.09.011

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  36 in total

Review 1.  NIH-FDA Analgesic Drug Development Workshop: translating scientific advances into improved pain relief.

Authors:  Raymond A Dionne; James Witter
Journal:  Clin J Pain       Date:  2003 May-Jun       Impact factor: 3.442

Review 2.  Attacking pain at its source: new perspectives on opioids.

Authors:  Christoph Stein; Michael Schäfer; Halina Machelska
Journal:  Nat Med       Date:  2003-08       Impact factor: 53.440

3.  Intrathecal opioids, potency and lipophilicity.

Authors:  Henry J McQuay; Ann F Sullivan; Karen Smallman; Anthony H Dickenson
Journal:  Pain       Date:  1989-01       Impact factor: 6.961

Review 4.  Can we conquer pain?

Authors:  Joachim Scholz; Clifford J Woolf
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

5.  Peripherally restricted opioid drugs: advances and retreats.

Authors:  Diane L DeHaven-Hudkins
Journal:  Curr Opin Anaesthesiol       Date:  2003-10       Impact factor: 2.706

6.  Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.

Authors:  Miguel Angel Benítez-Rosario; Manuel Feria; Antonio Salinas-Martín; Luis Pedro Martínez-Castillo; José Javier Martín-Ortega
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

7.  Methadone and heroin antinociception: predominant delta-opioid-receptor responses in methadone-tolerant mice.

Authors:  Jodie J Rady; Philip S Portoghese; James M Fujimo
Journal:  Jpn J Pharmacol       Date:  2002-03

8.  Methadone response in advanced cancer patients with pain followed at home.

Authors:  S Mercadante; A Casuccio; A Agnello; L Barresi
Journal:  J Pain Symptom Manage       Date:  1999-09       Impact factor: 3.612

9.  Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance.

Authors:  Y A Kolesnikov; S Jain; R Wilson; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

10.  Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal.

Authors:  Tanya Lewanowitsch; Rodney J Irvine
Journal:  Eur J Pharmacol       Date:  2002-06-07       Impact factor: 4.432

View more
  10 in total

1.  Determination of the unbound fraction of R- and S-methadone in human brain.

Authors:  Xiulu Ruan; Ken F Mancuso; Alan David Kaye
Journal:  Int J Legal Med       Date:  2016-07-25       Impact factor: 2.686

2.  Low-dose morphine elicits ventilatory excitant and depressant responses in conscious rats: Role of peripheral μ-opioid receptors.

Authors:  Fraser Henderson; Walter J May; Ryan B Gruber; Alex P Young; Lisa A Palmer; Benjamin Gaston; Stephen J Lewis
Journal:  Open J Mol Integr Physiol       Date:  2013-08-01

3.  Chronic ethanol consumption in rats produces opioid antinociceptive tolerance through inhibition of mu opioid receptor endocytosis.

Authors:  Li He; Jennifer L Whistler
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

4.  Role of central and peripheral opiate receptors in the effects of fentanyl on analgesia, ventilation and arterial blood-gas chemistry in conscious rats.

Authors:  Fraser Henderson; Walter J May; Ryan B Gruber; Joseph F Discala; Veljko Puskovic; Alex P Young; Santhosh M Baby; Stephen J Lewis
Journal:  Respir Physiol Neurobiol       Date:  2013-11-24       Impact factor: 1.931

5.  Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphine.

Authors:  Yao-Chang Chiang; Tsai-Wei Hung; Cynthia Wei-Sheng Lee; Jia-Ying Yan; Ing-Kang Ho
Journal:  J Biomed Sci       Date:  2010-06-07       Impact factor: 8.410

6.  Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications.

Authors:  John F Peppin; Phillip J Albrecht; Charles Argoff; Burkhard Gustorff; Marco Pappagallo; Frank L Rice; Mark S Wallace
Journal:  Pain Ther       Date:  2015-01-29

7.  Physiological and analgesic effects of continuous-rate infusion of morphine, butorphanol, tramadol or methadone in horses with lipopolysaccharide (LPS)-induced carpal synovitis.

Authors:  Adriano B Carregaro; Gabrielle C Freitas; Martina H Ribeiro; Nathalia V Xavier; Renata G S Dória
Journal:  BMC Vet Res       Date:  2014-12-21       Impact factor: 2.741

8.  Convallatoxin enhance the ligand-induced mu-opioid receptor endocytosis and attenuate morphine antinociceptive tolerance in mice.

Authors:  Po-Kuan Chao; Hsiao-Fu Chang; Li-Chin Ou; Jian-Ying Chuang; Pin-Tse Lee; Wan-Ting Chang; Shu-Chun Chen; Shau-Hua Ueng; John Tsu-An Hsu; Pao-Luh Tao; Ping-Yee Law; Horace H Loh; Shiu-Hwa Yeh
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

9.  Synthesis, Biological, and Structural Explorations of New Zwitterionic Derivatives of 14- O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives.

Authors:  Mariana Spetea; Silvia B Rief; Tanila Ben Haddou; Monika Fink; Elka Kristeva; Harald Mittendorfer; Stefanie Haas; Nora Hummer; Valeria Follia; Elena Guerrieri; Muhammad Faheem Asim; Sonja Sturm; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2019-01-03       Impact factor: 7.446

10.  Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone.

Authors:  G R Lauretti; C C Rizzo; A L Mattos; S W Rodrigues
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.